Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Wechsler ME, Colice G, Griffiths JM, Almqvist G, Skärby T, Piechowiak T, Kaur P, Bowen K, Hellqvist Å, Mo M, Garcia Gil E. Wechsler ME, et al. Among authors: skarby t. Respir Res. 2020 Oct 13;21(1):264. doi: 10.1186/s12931-020-01503-z. Respir Res. 2020. PMID: 33050928 Free PMC article. Clinical Trial.
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Sałapa K, Hellqvist Å, Almqvist G, Lal H, Kaur P, Skärby T, Colice G; SOURCE study group. Wechsler ME, et al. Among authors: skarby t. Lancet Respir Med. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29. Lancet Respir Med. 2022. PMID: 35364018 Clinical Trial.
Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Ferguson GT, Tashkin DP, Skärby T, Jorup C, Sandin K, Greenwood M, Pemberton K, Trudo F. Ferguson GT, et al. Among authors: skarby t. Respir Med. 2017 Nov;132:31-41. doi: 10.1016/j.rmed.2017.09.002. Epub 2017 Sep 5. Respir Med. 2017. PMID: 29229103 Free article. Clinical Trial.
Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.
Nylander S, Kull B, Björkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, Andersson M, Skärby T, Inghardt T, Fjellström O, Gustafsson D. Nylander S, et al. Among authors: skarby t. J Thromb Haemost. 2012 Oct;10(10):2127-36. doi: 10.1111/j.1538-7836.2012.04898.x. J Thromb Haemost. 2012. PMID: 22906130 Free article. Clinical Trial.
High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T, Jönsson P, Hjorth L, Behrentz M, Björk O, Forestier E, Jarfelt M, Lönnerholm G, Höglund P. Skärby T, et al. Cancer Chemother Pharmacol. 2003 Apr;51(4):311-20. doi: 10.1007/s00280-002-0552-1. Epub 2003 Mar 28. Cancer Chemother Pharmacol. 2003. PMID: 12721759
34 results